ERBB2 and breast carcinoma: Thus, the combination of TKIs with T-DM1 offers a more potent, comprehensive, and targeted treatment option for breast cancer patients, especially those who have developed resistance to traditional HER2-targeted therapies (Scaltriti et al., 2010).